• Isolated cells used for implantation
• Cells combined with biomaterials and active substances
• Biomaterial based scaffolds
• Administration of active substances to affect endogenous tissue

In addition, key technologies used in research as well as scientific and social issues will be presented and discussed. Market forecasts and shares will be presented for existing products and estimates for new product entries will be presented and will include any type or level of product displacement.

Over 70 companies will be presented who are either existing suppliers and/or have active R&D programs.

Download a Flyer (Acrobat Reader required)

Additional Information

Scope and Content of Report

Tissue engineering and its enabling technologies have developed over the past decade. As a result, the definition of tissue engineering has broadened. Many of the enabling and complementary technologies impacting tissue engineering, such as stem cell technologies, xenotransplantation, and acellular biomatrix technologies have been considered by some to be part of tissue engineering. This report contains information primarily on companies involved in core tissue engineering areas. We have chosen to exclude pure stem cell research, gene and cell therapies from this report because they are the subjects of an upcoming separate report.

The report includes profiles and information on over 45 companies involved in tissue engineering. Companies in this report include: Aastrom Biosciences, Advanced Tissue Sciences, BioHybrid Technologies, Biotransplant, Circe Biomedical, Collagen, Circe, Diacrin, Encelle, Genzyme BioSurgery, Integra Life Sciences, Islet Technology, LifeCell, Organogenesis, Orquest, Osiris Therapeutics, Osteotech, ReGen Biologics, and VivoRx.

Because of the early stages of product development, near-term estimates on products currently in development would be speculation. As such, we have attempted to identify the size of the market for current therapies for which the respective tissue engineering technology may enter or replace. The vast majority of products to be discussed have yet to be licensed, and we expect that by 2005, projections made here will be seen as quite inaccurate. Because this is a very rapidly developing field, readers are advised to use these estimates and the reasoning behind them as a starting point for developing market assessments, and to supplement them with developments that take place subsequent to the publishing of this project.

Methodology

The information in this report was taken from primary industry sources: interviews with company, government, and academic organization officials; company submissions such as 10K reports to the SEC; annual reports; biotechnology analyst reports; trade journals; and medical literature. The author contacted over 80 companies and individuals involved in the development of tissue engineering products.

The Brave New World of Tissue Engineering

New! the Tissue Engineering report, published by Kalorma Information is now available through MarketResearch.com. This study examines the most current products available and under development in the ‘brave new world” of tissue engineering. Some of the topics included in this report are:

• Isolated Cells used for implantation
• Cells combined with biomaterials and active substances
• Biomaterial based scaffolds

There are few areas of study and development that receive as much attention in both scientific and lay press as tissue engineering. In this report some of the leading tissue engineering product features as well as benefits are examined. Current market forecasts and market shares in this industry are presented in addition to the market forecast for new product entries. This report is key for anyone interested in understanding the market of this new and exciting industry.

Some of the issues addressed in this report are:

• The Impact of New Products and Emerging Technologies
• Acquisitions or divestitures
• Reasons for Growth or Decline in the Market

Key technologies used in research as well as scientific and social issues are covered. Over 70 companies have been profiled in this report that are either existing suppliers and/or have active research and development programs.

The Tissue Engineering report is available through MarketResearch.com, the leading provider of global market intelligence products and services. With MarketResearch.com, you can purchase The Tissue Engineering report as a complete study, or buy discrete segments using the options below:

• MarketLooks – concise, graphic-rich summaries of full-length market research reports available for online delivery. These PowerPoint slides provide industry high points in a presentation-ready format.
• Buy By the Slice – a cost-effective option that enables you to select and purchase exactly what you value most.

Issues Addressed:

• Key Market issues
• Demographics
• Reasons for Growth or Decline in the Market
• Advent of New Technologies
• Scientific and Social Issues
• The Impact of New Products and Emerging Technologies
• Acquisitions or divestures

Categories Covered:

• Demographics & Description of Industry and Potential Disease Modalities
• The Products
• Market Forecasts & Market Shares
• Company Profiles
• Strategic Issues and Conclusions
• Summary Conclusion

Companies/Sites Discussed:

• Astrom Biosciences
• Acorda Therapeutics
• Advanced Skin Cell Therapeutics
• Diacrin, Inc.
• FibroGen
• INAMED Corp.
• MorphoGen Pharmaceuticals
• Osteotech
• Spinal Concepts Inc.
• Titan Pharmaceuticals
• VivoRx Inc.

Press Release

“Market Potential for Tissue Engineering Estimated at $80 Billion”

New York, August 8, 2001/PR Newswire—Engineered and regenerated tissues have a market potential of $80 Billion dollars, according to a new study released today from Kalorama Information, a division of MarketResearch.com, and the race is on to begin capitalizing on this huge unmet need.

According to the report, entitled Emerging Technologies and Opportunities in Structural Tissue Engineering, a growing number of companies spent nearly $600 million last year pursuing tissue engineering solutions to a vast array of diseases and degenerative conditions, including dermatologic, orthopedic, cardiovascular, and liver and pancreatic conditions. Almost 70 companies are actively developing products and enabling technologies.

The study found that despite the enormous potential for this industry, there are several major hurdles to overcome, both technical and financial. In particular, funding was identified as one of the industry’s greatest concerns.

“FDA approval requires long financial staying power,” noted Steven Heffner, Kalorama’s Acquisitions Editor. “Many smaller companies will have to seek out partnering opportunities to see their technologies through to the market place.”

The three currently approved tissue-engineered products had combined sales of only $49 million in 2000, according to the report, and the industry in general is predicted to run at a significant net loss for a few more years. However, the clinical and monetary potential combined with many promising technical developments should sustain the current 24% growth in research spending.

Produced by Kalorama Information, a division of MarketResearch.com, Emerging Technologies and Opportunities in Structural Tissue Engineering is a comprehensive, in-depth analysis of technologies, players, trends, and opportunities in the tissue engineering sector worldwide.

The report forecasts sales data and market shares through 2005. Future products and technologies, including production issues, are also examined with estimates of time to entry and projections for the first 5 years.

Related Reports:
Regenerative Medicines: Bone and Joint Applications
Biotechnology Sector
The World Market for Biosimilars and the Potential for US Follow-on Biologics
Cell Therapy Clinical Trial Analysis
Stem Cell Markets
Biotechnology Sector
Stem Cell Research and Tissue Engineering: A Boon for Dental Tissue Regeneration
Biotechnology Sector
The 2009 Report on Gene Expression Services: World Market Segmentation by City
The 2009-2014 Outlook for Gene Expression Services in Japan